S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

Autor: Per Pfeiffer, K R Schønnemann, Stine Braendegaard Winther, Mathilde Weisz Ejlsmark, Merete Krogh, Jon Kroll Bjerregaard, Helle Anita Jensen

Publikováno v: Winther, S B, Bjerregaard, J K, Schonnemann, K R, Ejlsmark, M W, Krogh, M, Jensen, H A & Pfeiffer, P 2018, ' S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma ', Cancer Chemotherapy and Pharmacology, vol. 81, no. 3, pp. 573–578 . https://doi.org/10.1007/s00280-018-3528-5

PURPOSE: Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades. Randomized, primarily Japanese, studies have shown promising efficacy when combined with S-1 (GemS-1); however, no data are published i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9970c5b1ee7299ad820c5800d2fedc51
https://doi.org/10.1007/s00280-018-3528-5

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial

Autor: Lionnel Geoffrois, Remy Delva, N. Houede, Frederic Rolland, Agnès Laplanche, J.-C. Eymard, B. Laguerre, Aude Flechon, Karim Fizazi, Stéphane Culine, D. Burcoveanu, G. Gravis, Christine Chevreau

Publikováno v: Annals of Oncology
Annals of Oncology, Oxford University Press (OUP), 2014, 25, pp.987--91. ⟨10.1093/annonc/mdu099⟩
Annals of Oncology, Elsevier, 2014, 25, pp.987--91. ⟨10.1093/annonc/mdu099⟩

International audience; BACKGROUND: The standard treatment of patients with metastatic germ-cell tumor (GCT) relapsing after first-line chemotherapy is based on a cisplatin and ifosfamide-containing three-drug regimen, which usually yields a complete

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304b4e6899b4eb1b6e5d6e2e53e885ab
https://doi.org/10.1093/annonc/mdu099

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas

Autor: Antoine Hollebecque, Sonia Extremera, Gilles Salles, Vicente Alfaro, Sandrine Aspeslagh, Mark N. Stein, Emmanuel Gyan, Salvador Fudio, Rastilav Bahleda, Arturo Soto-Matos, Jean-Charles Soria

Publikováno v: Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩

International audience; This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced cancer and lymphoma patients. The study included two treatment arm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23b85d24896c8e6b050b4cfb9ec050c
https://hal.archives-ouvertes.fr/hal-01791282

A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors

Autor: John Souglakos, Periklis Pappas, Marios Marselos, Dimitris Mavroudis, Martha Nikolaidou, Nikolaos Vardakis, Athanasios Kotsakis, Zacharenia Saridaki, Vassilis Georgoulias

Publikováno v: Cancer Chemotherapy and Pharmacology. 65:121-128

PURPOSE: To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of the paclitaxel, gemcitabine, oxaliplatin combination administered biweekly in patients with advanced solid tumors. PATIENTS AND METHODS: Patients rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::402e266684e35d2b52bc436ecadaa547
https://doi.org/10.1007/s00280-009-1013-x

Preoperative Concomitant Hyperfractionated Radiotherapy and Gemcitabine for Locally Advanced Rectal Cancers

Autor: Pascal Gervaz, Claudio Soravia, Philippe Morel, Sabine Bieri, Abdelkarim S. Allal, Arnaud Roth, Jacques Bernier, Philippe Gertsch

Publikováno v: Cancer Journal, Vol. 11, No 2 (2005) pp. 133-9

The purpose of this study was to determine the maximum tolerated dose of gemcitabine when it was administered concomitantly with hyperfractionated radiotherapy before surgery in patients with locally advanced rectal cancers and to investigate the mid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9974142c38870fe7fa23b9c685042cee
https://doi.org/10.1097/00130404-200503000-00008